Q Line Biotech IPO Final Day: GMP ₹120 (₹-5)
It’s the final bell for the Q Line Biotech SME IPO on the NSE, and we’re on Day 5, the closing day! As the subscription window slams shut today, May 25, 2026, investors are making their last-minute decisions. The issue price is fixed at ₹326 per share, with a lot size of 400 shares. We’ve seen a lot of buzz around this biotech player, and today’s subscription numbers are crucial to understanding the market’s appetite.
| Date | GMP | Est. Listing |
|---|---|---|
| 28 May | +₹115 | ₹458 |
| 27 May | +₹100 | ₹443 |
| 26 May | +₹100 | ₹443 |
| 25 May | +₹120 | ₹463 |
| 23 May | +₹120 | ₹463 |
Subscription Status
As of the latest updates, the subscription figures for Q Line Biotech are showing 0x across all categories – Retail, NII (High Net-worth Individuals), and QIB (Qualified Institutional Buyers), with a total of 0x. Now, this might seem a little alarming at first glance, especially on the closing day. However, it’s important to remember that SME IPOs often see a significant surge in subscriptions on the very last day, particularly in the final hours. Many investors prefer to wait until they have a clearer picture of the overall demand and the grey market premium before committing their funds. The absence of immediate overwhelming demand doesn’t necessarily mean a lack of interest; it could simply indicate a strategic waiting game from potential applicants. We’ll need to keep a close eye on these numbers as the day progresses.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 71.44x | |
| NII / HNI | 146.33x | |
| QIB | 123.94x | |
| Total | 102.49x |
| Date | Retail | NII | QIB | Total |
|---|---|---|---|---|
| 25 May | 71.44x | 146.33x | 123.94x | 102.49x |
| 22 May | 9.92x | 15.96x | 5.19x | 9.86x |
| 21 May | 3.61x | 5.24x | 4.15x | 4.11x |
GMP Update
The Grey Market Premium (GMP) for Q Line Biotech IPO currently stands at ₹120. Yesterday, it was hovering around ₹125, meaning there’s been a slight decrease of ₹5. While a ₹5 dip might not sound like much, it’s a point of observation. A strong GMP generally indicates robust investor sentiment and expectations of a good listing. The current GMP of ₹120 still suggests a healthy potential listing price of around ₹446 (Issue Price ₹326 + GMP ₹120). This is encouraging, as it points towards a potential profit of approximately 36.8% on listing day. However, the slight downward trend from yesterday is something to monitor. It could be a natural fluctuation as the IPO closes, or it might signal a slight cooling of speculative interest. The bottom line is, the GMP remains positive and points towards a profitable debut.
Should You Apply?
So, the big question: should you still be applying for Q Line Biotech shares on this closing day? It’s a mixed bag, isn’t it? On one hand, the subscription numbers are currently flat, which could be a sign of caution from some investors, or simply a prelude to a last-minute rush. On the other hand, the GMP, despite a minor dip, is still strong and suggests a favorable listing. If you’re considering applying, it’s crucial to do your own due diligence. Look at the company’s fundamentals, its business model, and its future prospects. The current GMP indicates a potential upside, but the market is unpredictable. As SEBI registered investment advisors often remind us, IPOs are subject to market risks. If you’re comfortable with the risk-reward profile and believe in Q Line Biotech’s long-term potential, then applying might be a good move. However, if you’re solely relying on listing gains and are wary of the current subscription data, it might be prudent to wait and see the final subscription figures and the post-listing performance. Remember, it’s always wise to consult with a financial advisor before making any investment decisions.